ann: data from final cohort of patients, page-130

lol where do you get that from ?

Not sure why your lol'd. You were one predicting a re-rating on '4th cohort' announcement.

of course Patrys will be in a better position to run post RI

Sure if 1. the placement is successful, and 2. if successful, once the 50% dilution can be soaked up

they'll have no trouble placing any shortfall through the RI they where really just doing the right thing by making it pro-rata after the upset the last time they moved for capital over and beyond registry wide.

Another assumption. How do you know they will have no trouble placing any shortfall? If the share price hangs around these levels they may very well have great difficult in placing the shortfall.

PAB with the $15M in bank will be position of strength.

$15mill is earmarked for spending. No doubt it will allow them to produce the material they need to get Onyx trials underway, which is why they need a successful placement. Otherwise the market, rightly or wrongly, may view the lack of success as a potential delaying factor for commencement of Phase 2 trials.